{"id":964601,"date":"2026-05-19T08:58:04","date_gmt":"2026-05-19T12:58:04","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/icecures-prosense-reports-nearly-90-recurrence-free-rate-for-cryoablation-of-kidney-cancer-data-presented-at-ecio-2026-and-first-ever-breast-cryoablation-master-class-overbooked\/"},"modified":"2026-05-19T08:58:04","modified_gmt":"2026-05-19T12:58:04","slug":"icecures-prosense-reports-nearly-90-recurrence-free-rate-for-cryoablation-of-kidney-cancer-data-presented-at-ecio-2026-and-first-ever-breast-cryoablation-master-class-overbooked","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/icecures-prosense-reports-nearly-90-recurrence-free-rate-for-cryoablation-of-kidney-cancer-data-presented-at-ecio-2026-and-first-ever-breast-cryoablation-master-class-overbooked\/","title":{"rendered":"IceCure’s ProSense\u00ae Reports Nearly 90% Recurrence-Free Rate for Cryoablation of Kidney Cancer: Data Presented at ECIO 2026 and First-Ever Breast Cryoablation Master Class Overbooked"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n At the annual European Conference on Interventional Oncology, ICESECRET data presented demonstrated 89.4% recurrence-free rate in patients with tumors \u22643 cm and 83.9% of patients remained recurrence-free at a median follow-up of 4.0 years<\/i>\n <\/p>\n

\n Independent breast cancer study reported no residual cancer at 6 and 12 months post-procedure, with 100% of patients reporting excellent cosmetic outcomes <\/i>\n <\/p>\n

\n Independent study showed 92.9% reduction in fibroadenoma volume at 12 months post-treatment with ProSense\u00ae<\/i>\n <\/p>\n

\n FDA clearance of ProSense\u00ae in early-stage breast cancer drives expanding global adoption and clinical interest in breast cryoablation<\/i>\n <\/p>\n

\n CAESAREA, Israel<\/span>, May 19, 2026<\/span> \/PRNewswire\/ — IceCure Medical Ltd.<\/a> (NASDAQ: ICCM) (“IceCure”, “IceCure Medical” or the “Company”), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that cryoablation and ProSense\u00ae were featured at the annual European Conference on Interventional Oncology (“ECIO<\/a>“) 2026, held in Basel, Switzerland on April 26 to 30, 2026.<\/p>\n

\n \"IceCure\n <\/div>\n

“We believe ECIO 2026 marked a significant milestone for IceCure, ProSense\u00ae and cryoablation in interventional oncology,” said Eyal Shamir, Chief Executive Officer of IceCure. “We are experiencing growing global momentum and commercial interest in ProSense\u00ae and cryoablation, with particular interest shown at ECIO 2026 in the treatment of breast cancer, fibroadenomas, and kidney cancer. The eager participation of doctors who are regular users of ProSense\u00ae<\/span> leading hands-on trainings and presentations and more independent third-party data, combined with the compelling kidney cancer results from the ICESECRET trial, reinforce the expanding clinical validation and versatility of our technology.”<\/p>\n

For the first time in ECIO’s history, a dedicated breast cryoablation course was held, including hands-on training with ProSense\u00ae conducted by leading ProSense\u00ae users: Dr. Franco Orsi of the European Institute of Oncology, Milan and Principal Investigator of the PRECICE<\/a> trial, Dr. Toulsie Ramothul of Institute Curie and Principal Investigator of the CRYODESC trial, and Dr. Linda Riks of the Franciscus Gasthuis & Vlietland Hospital, Rotterdam, Investigator of the THERMAC<\/a> trial. In addition, ProSense\u00ae was featured in three general cryoablation device hands-on training sessions.<\/p>\n

“Our leadership role at ECIO 2026 included the first dedicated breast cryoablation course, which was overbooked due to the very high level of interest. Most of the faculty mentioned ICE3, ProSense\u00ae’s U.S. Food and Drug Administration authorization, the recent American Society of Breast Surgeons’ updated guidelines, and data from other trials, underscoring the increasing recognition of cryoablation as a minimally invasive alternative to surgery and its potential to become a standard-of-care treatment option,” Shamir concluded.<\/p>\n

\n Clinical Data Highlights<\/b>\n <\/p>\n

\n ICESECRET Trial \u2013 Kidney Cancer, 5-Year Results<\/b>\n <\/p>\n

Abstract title: ICESECRET Trial Final analysis: 5-year Safety and Efficacy of Cryoablation for Small Renal Masses<\/i>
Final analysis of the ICESECRET prospective multicenter trial evaluated cryoablation using ProSense\u00ae for small renal masses:<\/p>\n